Auris Medical Holding Ltd. . (NASDAQ: EARS), a clinical-stage company devoted to developing therapeutics that meet critical unmet medical needs in neurotology, rhinology, allergy, and CNS disorders, today announced positive efficacy data from the in vitro test known from AM-301. AM-301 is a drug-free nasal spray developed by the company’s subsidiary, Altamira Medica, to protect against airborne pathogens and allergens.
AM-301 was tested for its ability to prevent or mitigate SARS-CoV-2 infection of nasal epithelial cells, which are part of the nasal mucosa and the first barrier to continuously inhaled substances such as pathogens and allergens. The experiment was conducted over four days on reconstituted human nasal epithelia, which are widely used to study the effects of human respiratory viruses. In control cultures treated with saline solution, Sars-CoV-2 replicated efficiently, resulting in a rapid increase in virus titer (measured with the Median Tissue Culture Infectious Dose, TCID50). . In contrast, daily treatment with AM-301, which began immediately prior to inoculation, demonstrated effective protection against viral infections. The mean virus titers were 90 48 hours after infection. 0% lower than those observed in controls (p)
« We are very pleased that the protective effect of AM-301 against Sars-CoV-2 has been confirmed in an assay that very closely simulates the real conditions in the human nose, » commented Thomas Meyer, Founder, Chairman and CEO from Auris Medical. Our first experiments in September showed that the key component of AM-301 captured up to 99% of Sars-CoV-2 when placed in contact with a virus suspension. With our newly developed spray formulation, we now have direct evidence that AM-301 can significantly reduce the risk of nasal cell infection. We look forward to running AM-301 through additional testing and moving the program forward to regulatory filing in 2021. one????
Get full access to all new and archived articles, unlimited portfolio tracking, email notifications, custom newswires and RSS feeds – and much more!
Auris Medical Holding
EbeneMagazine – CA – Auris Medical Holding (EARS) reports positive in vitro efficacy data for AM-301 in protecting against Sars-CoV-2 infections
. . Related title :
– Auris Medical increases after AM-301 shows encouraging preclinical measures against SARS-CoV-2 infections
– Auris Medical Holding (EARS) reports positive in vitro efficacy data for AM-301 in protection against Sars-CoV-2 . . .
– Auris Medical reports positive in- Vitro efficacy data for AM -301 in protection against Sars-CoV-2 infection